Literature DB >> 15207808

Metabolism of 2-methyladenosine in Mycobacterium tuberculosis.

William B Parker1, Esther W Barrow, Paula W Allan, Sue C Shaddix, Mary C Long, William W Barrow, Namita Bansal, Joseph A Maddry.   

Abstract

2-Methyladenosine (methyl-Ado) has selective activity against Mycobacterium tuberculosis (M. tuberculosis). In an effort to better understand its mechanism of action, we have characterized its metabolism in M. tuberculosis cells. The primary intracellular metabolite of methyl-Ado was 2-methyl-adenylate (methyl-AMP). Very little of the methyl-AMP was metabolized further. A M. tuberculosis strain that was resistant to methyl-Ado did not express adenosine kinase and did not convert methyl-Ado to methyl-AMP in intact cells. In contrast to these results, the primary intracellular metabolite of adenosine in M. tuberculosis cells was ATP, which was readily incorporated into RNA. The rate of metabolism of methyl-Ado to methyl-AMP was similar to the rate of metabolism of adenosine to ATP. Treatment of M. tuberculosis with methyl-Ado did not affect intracellular ATP levels. Methyl-Ado and Ado were also cleaved to 2-methyladenine and adenine, respectively, which accumulated in the medium outside the cells. These studies suggested that methyl-AMP was the active metabolite responsible for the cytotoxicity of this agent. Furthermore, because methyl-Ado was poorly metabolized in human cells, these studies indicated that the selective activity of methyl-Ado was due to its selective activation by M. tuberculosis. These studies have identified two enzyme reactions (Ado kinase and Ado cleavage) in M. tuberculosis that could be exploited for the rational design of new and selective anti-M. tuberculosis agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207808     DOI: 10.1016/j.tube.2004.02.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  7 in total

1.  Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia.

Authors:  Yao Li; Wei Wang; William Parker; J P Clancy
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-06       Impact factor: 6.914

2.  Identification and characterization of two adenosine phosphorylase activities in Mycobacterium smegmatis.

Authors:  Kajal Buckoreelall; Landon Wilson; William B Parker
Journal:  J Bacteriol       Date:  2011-08-05       Impact factor: 3.490

3.  A high-affinity adenosine kinase from Anopheles gambiae.

Authors:  María B Cassera; Meng-Chiao Ho; Emilio F Merino; Emmanuel S Burgos; Agnes Rinaldo-Matthis; Steven C Almo; Vern L Schramm
Journal:  Biochemistry       Date:  2011-02-15       Impact factor: 3.162

4.  Overexpression, purification and crystallographic analysis of a unique adenosine kinase from Mycobacterium tuberculosis.

Authors:  Yimin Wang; Mary C Long; Senthil Ranganathan; Vincent Escuyer; William B Parker; Rongbao Li
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-06-01

5.  Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety.

Authors:  Mary C Long; Sue C Shaddix; Omar Moukha-Chafiq; Joseph A Maddry; Lisa Nagy; William B Parker
Journal:  Biochem Pharmacol       Date:  2008-02-02       Impact factor: 5.858

6.  Identifying feasible metabolic routes in Mycobacterium smegmatis and possible alterations under diverse nutrient conditions.

Authors:  Priyanka Baloni; Jyothi Padiadpu; Anupam Singh; Kuldeepkumar R Gupta; Nagasuma Chandra
Journal:  BMC Microbiol       Date:  2014-11-18       Impact factor: 3.605

7.  Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.

Authors:  Roberto A Crespo; Qun Dang; Nian E Zhou; Liam M Guthrie; Thomas C Snavely; Wen Dong; Kimberly A Loesch; Takao Suzuki; Lanying You; Wei Wang; Theresa O'Malley; Tanya Parish; David B Olsen; James C Sacchettini
Journal:  J Med Chem       Date:  2019-04-19       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.